GlobeNewswire: BridgeBio Pharma, Inc. Contains the last 10 of 190 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T06:34:48ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/06/2841039/0/en/BridgeBio-Pharma-Announces-Pricing-of-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=55514BridgeBio Pharma Announces Pricing of Public Offering of Common Stock2024-03-06T04:53:56Z<![CDATA[PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 shares of its common stock at a public offering price of $29.00 per share, before deducting underwriting discounts and commissions. In addition, BridgeBio has granted the underwriters a 30-day option to purchase up to an additional 1,293,103 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $250.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering to be sold by BridgeBio.]]>https://www.globenewswire.com/news-release/2024/03/04/2839991/0/en/BridgeBio-Pharma-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=55514BridgeBio Pharma Announces Proposed Public Offering of Common Stock2024-03-04T21:17:36Z<![CDATA[PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $250 million of shares of its common stock. BridgeBio also intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares in the proposed offering are to be sold by BridgeBio.]]>https://www.globenewswire.com/news-release/2024/03/04/2839242/0/en/BridgeBio-Pharma-and-Bayer-Announce-European-Licensing-Agreement-for-Acoramidis-in-ATTR-CM.html?f=22&fvtc=4&fvtv=55514BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM2024-03-04T07:30:00Z<![CDATA[- BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe]]>https://www.globenewswire.com/news-release/2024/02/22/2833578/0/en/BridgeBio-Pharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Business-Update.html?f=22&fvtc=4&fvtv=55514BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update2024-02-22T12:30:00Z<![CDATA[- Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on positive results of Phase 3 ATTRibute-CM trial, which were published in the New England Journal of Medicine; NDA has been accepted for review with a PDUFA date of November 29, 2024; Marketing Authorization Application (MAA) for acoramidis has also been accepted by the European Medicines Agency (EMA)]]>https://www.globenewswire.com/news-release/2024/02/07/2825095/0/en/BridgeBio-Pharma-and-Kyowa-Kirin-Announce-Partnership-with-an-Upfront-Payment-of-100-Million-for-an-Exclusive-License-on-Infigratinib-in-Skeletal-Dysplasias-in-Japan.html?f=22&fvtc=4&fvtv=55514BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan2024-02-07T12:34:22Z<![CDATA[- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan]]>https://www.globenewswire.com/news-release/2024/02/06/2824201/0/en/BridgeBio-Pharma-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=55514BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)2024-02-06T12:30:00Z<![CDATA[PALO ALTO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on February 05, 2024, the compensation committee of BridgeBio’s board of directors granted thirty-five new employees restricted stock units for an aggregate of 123,838 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on February 16, 2025, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).]]>https://www.globenewswire.com/news-release/2024/02/05/2823433/0/en/BridgeBio-Pharma-Announces-U-S-Food-and-Drug-Administration-FDA-Acceptance-of-New-Drug-Application-NDA-for-Acoramidis-for-the-Treatment-of-Patients-with-Transthyretin-Amyloid-Cardi.html?f=22&fvtc=4&fvtv=55514BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)2024-02-05T12:30:00Z<![CDATA[- Accepted with Prescription Drug User Fee Act (PDUFA) action date of November 29, 2024; FDA not currently planning to hold an advisory committee meeting to discuss application]]>https://www.globenewswire.com/news-release/2024/02/02/2822760/0/en/BridgeBio-Pharma-Shares-Positive-Results-of-Single-Arm-Phase-3-Study-of-Acoramidis-in-Japanese-Patients-with-Transthyretin-Amyloid-Cardiomyopathy-ATTR-CM-Including-No-Mortality-Rep.html?f=22&fvtc=4&fvtv=55514BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months2024-02-02T12:00:00Z<![CDATA[- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial]]>https://www.globenewswire.com/news-release/2024/01/18/2811408/0/en/BridgeBio-Pharma-Secures-up-to-1-25-Billion-of-Capital-from-Blue-Owl-and-CPP-Investments-to-Accelerate-the-Development-and-Launch-of-Genetic-Medicines.html?f=22&fvtc=4&fvtv=55514BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines2024-01-18T12:00:00Z<![CDATA[- The raise includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis]]>https://www.globenewswire.com/news-release/2024/01/10/2807550/0/en/BridgeBio-Pharma-Announces-Publication-of-Positive-Results-from-Phase-3-ATTRibute-CM-Study-of-Acoramidis-for-Patients-with-Transthyretin-Amyloid-Cardiomyopathy-ATTR-CM-in-the-New-E.html?f=22&fvtc=4&fvtv=55514BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine2024-01-10T22:15:42Z<![CDATA[- ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality (ACM) and frequency of cardiovascular-related hospitalization (CVH)), with a Win Ratio of 1.8 (p<0.0001)]]>